Ascend Advanced Therapies

Even as advanced #medicines innovation continues, challenges remain. One of those can be the cost of running processes from research to commercial phases (lab space, equipment, #labor, etc.). How can working with a #contract manufacturer help streamline costs and increase #quality? Our own Iain McGhee is referenced here as industry experts weigh in to BioPharm International and Pharmaceutical Technology. https://lnkd.in/gyHsXJai

#Collaboration is critical to success in #cellandgenetherapies. Read about how we worked with Sartorius to solve the AAV scalability challenge, demonstrating consistent productivity, quality, and potency from 250 mL to 200 L scales. https://lnkd.in/etsunhty

Alachua, Florida was incorporated in 1905, with deep roots in farming and engineering. But did you know that it was the original home to #genetherapy, too? Cynthia Challener provides an up about this #history of #innovation in our latest insight: https://lnkd.in/gGMhjq3h

Can you believe it's been a month since the European Society of Gene and Cell Therapy Congress in Rome? We are #thankful for a great time during the event, sharing information and making #connections on the latest in advanced therapies. Here's a look back at our time onsite, and our posters from the event can be found here: https://lnkd.in/dD3-_MJ8

Did you hear our #news? What a great week it has been connecting with our new colleagues. Together, we can help move the dial of #advancedtherapies progress farther! https://lnkd.in/eAYwrgds

Thank you to Fierce Pharma for helping to tell our story. We are honored to be here, working together with the team from ABL to build the future of #advancedtherapies together! https://lnkd.in/dzJ2acHJ

We continue growing and evolving. Today, we are thrilled to align with ABL to deepen our commitment to being an exceptional advanced #therapies #partner. The addition of the ABL Rockville team and facility aligns more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated virus (AAV) production. The merger also expands fill/finish capacity in the US making the combined group one of the few suppliers with a comprehensive R&D to commercial offering in the market. https://lnkd.in/eAYwrgds

According to the Q3 2024 American Society of Gene & Cell Therapy report, "2,042 gene therapies (including genetically modified #cell therapies such as CAR-T cell therapies) are in development, accounting for 49% of gene, cell, and RNA therapies." It is hard to believe the amount of progress being made, and there is only more #genetherapy #innovation on the horizon! Read the full report here: https://lnkd.in/gvJwu4Yd

How do you develop a fully scalable #genetherapy process with high product yield and vector #quality? Our team explored this topic in ESGCT poster 0031 in Rome last month: https://lnkd.in/eP7H7f3Y

Look at this whole team dressed up as builders of the #future of #genetherapy! It's spooky 🎃 what a bootifiul time we had in Rome last week at the European Society of Gene and Cell Therapy Congress connecting & sharing our passion for progress. Thank you for visiting and feel free to reach out any time at business@ascend-adv.com. Are you in a fright that you didn't get a chance to see our team or posters onsite? Have we got a treat for you: https://lnkd.in/dD3-_MJ8